AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28

AtriCure, Inc.

2024-Q1 EPS reported -$0.28 revenue$108,851,000

Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).
GAAP net loss $0.28 per share vs $0.14 loss in Q1 2023; operating loss $10.9M (includes $4M prior-year legal settlement gain).
Adjusted EBITDA $2.8M vs $1.9M a year ago; adjusted loss per share $0.25 vs $0.23.
Gross margin 74.7%, up 21 bps YoY on favorable product/geographic mix.
CEO cites strong start with growth across all franchises; new product launches and clinical research ahead.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.